Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Schrodinger, Inc. Stock Research

SDGR

27.55USD+0.11(+0.40%)Delayedas of 27 Sep 2023, 02:48 pm
Watchlist

Market Summary

USD27.55+0.11
Delayedas of 27 Sep 2023, 02:48 pm
0.40%

SDGR Alerts

  • Big jump in Earnings (Y/Y)

SDGR Stock Price

SDGR RSI Chart

SDGR Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

29.63

Price/Sales (Trailing)

10.14

EV/EBITDA

21.67

Price/Free Cashflow

-17.07

SDGR Price/Sales (Trailing)

SDGR Profitability

Operating Margin

60.25%

EBT Margin

20.73%

Return on Equity

2.44%

Return on Assets

1.72%

Free Cashflow Yield

-5.86%

SDGR Fundamentals

SDGR Revenue

Revenue (TTM)

193.8M

Revenue Y/Y

-8.53%

Revenue Q/Q

-45.68%

SDGR Earnings

Earnings (TTM)

66.4M

Earnings Y/Y

108.97%

Earnings Q/Q

-96.69%

Price Action

52 Week Range

15.8559.24
(Low)(High)

Last 7 days

-12.0%

Last 30 days

-21.9%

Last 90 days

-38.7%

Trailing 12 Months

14.6%

SDGR Financial Health

Current Ratio

4.89

SDGR Investor Care

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SDGR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Herman Jenny
acquired
5,454
1.2
4,545
svp & controller
2023-08-09
Dugan Margaret
acquired
-
-
15,000
chief medical officer
2023-08-09
Lorton Kenneth Patrick
sold
-400,642
40.0642
-10,000
evp & chief technology officer
2023-06-30
Tran Yvonne
sold
-602,000
50.00
-12,040
evp, clo & cpo
2023-06-30
Tran Yvonne
acquired
204,680
17.00
12,040
evp, clo & cpo
2023-06-15
OBEROI ARUN
acquired
-
-
6,250
-
2023-06-15
Friesner Richard
acquired
-
-
6,250
-
2023-06-15
Kapeller-Libermann Rosana
acquired
-
-
6,250
-
2023-06-15
Lynton Michael
acquired
-
-
6,250
-
2023-06-15
Sender Gary
acquired
-
-
6,250
-

1–10 of 50

Which funds bought or sold SDGR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
2.34
984,000
2,031,000
-%
2023-09-13
CGC Financial Services, LLC
new
-
210,712
210,712
0.14%
2023-08-23
WOLVERINE TRADING, LLC
reduced
-78.48
-579,588
399,412
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
4,110
3,086,520
3,125,710
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.31
1,612,980
3,505,680
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
889,000
889,000
0.01%
2023-08-18
Legato Capital Management LLC
new
-
258,086
258,086
0.04%
2023-08-16
Nuveen Asset Management, LLC
added
9.46
3,817,490
7,368,490
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
23.1
2,186,660
3,826,070
-%
2023-08-15
Parkside Financial Bank & Trust
added
7.00
2,709
5,342
-%

1–10 of 43

Latest Funds Activity

Are funds buying SDGR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SDGR
No. of Funds

Schedule 13G FIlings of Schrodinger

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 10, 2023
vanguard group inc
10.69%
6,669,820
SC 13G/A
Jul 07, 2023
blackrock inc.
13.5%
8,438,927
SC 13G/A
Feb 09, 2023
vanguard group inc
8.25%
5,120,349
SC 13G/A
Feb 03, 2023
blackrock inc.
6.4%
3,956,805
SC 13G
Feb 09, 2022
blackrock inc.
5.0%
3,057,148
SC 13G/A
Feb 04, 2022
blackrock inc.
5.1%
3,123,673
SC 13G
Dec 01, 2021
shaw david e
3.9%
2,401,777
SC 13G/A
Apr 26, 2021
shaw david e
17.2%
9,662,606
SC 13G/A
Feb 12, 2021
bill & melinda gates foundation trust
23.2%
16,145,857
SC 13G
Feb 10, 2021
vanguard group inc
6.76%
3,805,264
SC 13G

Recent SEC filings of Schrodinger

View All Filings
Date Filed Form Type Document
Sep 18, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 09, 2023
144
Notice of Insider Sale Intent
Aug 03, 2023
8-K/A
Current Report
Aug 03, 2023
3
Insider Trading
Aug 02, 2023
8-K
Current Report
Aug 02, 2023
10-Q
Quarterly Report
Jul 10, 2023
SC 13G/A
Major Ownership Report
Jul 07, 2023
SC 13G/A
Major Ownership Report

Peers (Alternatives to Schrodinger)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
167.5B
40.2B
-7.66% -3.16%
32.45
4.16
-11.68% -39.67%
35.9B
3.5B
-12.23% 30.55%
45.38
10.22
6.21% 19.20%
31.9B
2.2B
5.42% 26.20%
59.01
14.28
11.56% 37.20%
MID-CAP
5.5B
526.1M
-13.07% 8.40%
-133.78
10.44
74.86% 6.49%
4.6B
1.1B
-1.66% -2.00%
136.43
4.05
69.36% 3.03%
3.1B
2.5B
-13.70% -28.01%
-0.78
1.24
13.30% 59.30%
2.1B
1.2B
-21.26% -46.64%
-88.88
1.67
-1.77% -138.27%
-
-
-8.05% -1.80%
-
-
- -
SMALL-CAP
2.0B
193.8M
-21.93% 14.57%
29.63
10.14
18.78% 144.88%
278.7M
338.1M
0.29% 140.65%
-2.92
0.82
22.28% 17.91%
51.8M
24.5M
-0.49% 0.49%
-4.14
2.11
-24.11% 3.57%
1.3M
6.2M
-81.65% 3.23%
-0.06
0.21
-28.21% -7.22%

Schrodinger News

The Motley Fool
3 Artificial Intelligence (AI) Stocks That Could Soar More Than ....
The Motley Fool,
2 days ago
InvestorPlace
7 Stocks the Big Money Is Buying Now.
InvestorPlace,
29 days ago
InvestorsObserver
Genetic Engineering & Biotechnology News
Schrödinger's Equation: Physics + Machine Learning = Drug ....
Genetic Engineering & Biotechnology News,
40 days ago
The Motley Fool

Returns for SDGR

Cumulative Returns on SDGR

-17.7%


3-Year Cumulative Returns

Risks for SDGR

What is the probability of a big loss on SDGR?

97.4%


Probability that Schrodinger stock will be more than 20% underwater in next one year

84.8%


Probability that Schrodinger stock will be more than 30% underwater in next one year.

83.8%


Probability that Schrodinger stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SDGR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Schrodinger was unfortunately bought at previous high price.

Drawdowns

Financials for Schrodinger

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-1.7%193,794,000197,074,000180,955,000170,282,000163,152,000154,467,000137,931,000124,793,000120,740,000114,048,000108,095,000100,895,00095,058,00090,976,00085,543,00079,614,66779,502,00082,964,000
Gross Profit-2.8%115,408,000118,732,000101,022,00088,679,00082,593,00077,439,00065,620,00058,251,00062,408,00064,011,00063,472,00060,007,00055,446,00051,714,00049,093,00044,754,66745,710,00052,016,000
Operating Expenses5.4%281,743,000267,407,000247,839,000229,473,000211,898,000193,613,000177,063,000163,763,000148,691,000137,039,000124,388,000112,186,000103,472,00096,616,00087,808,00085,912,00084,862,00074,468,000
  S&GA Expenses4.8%34,710,00033,116,00030,642,00027,235,00025,630,00023,582,00022,150,00020,850,00019,263,00018,245,00017,795,00018,863,00020,079,00021,060,00021,364,00020,828,00020,872,00020,372,000
  R&D Expenses8.3%150,873,000139,291,000126,372,000116,975,000107,309,00097,278,00090,904,00083,078,00076,878,00072,443,00064,695,00058,458,00051,792,00044,666,00039,404,00037,762,66735,938,00033,752,000
EBITDA-100.0%-45,983,000-144,782,000-148,369,000-144,248,000-131,909,000-97,961,000-78,523,000-39,948,000-8,893,000-22,634,000-18,574,333-34,058,000-30,842,000-22,332,000---
EBITDA Margin-100.0%-0.23-0.80-0.87-0.88-0.85-0.71-0.63-0.33-0.08-0.21-0.18-0.36-0.34-0.26---
Earnings Before Taxes77.1%72,336,00040,836,000-149,126,000-152,224,000-147,577,000-134,827,000-100,808,000-81,728,000-43,462,000-12,561,000-26,292,000-22,105,000-37,574,000-34,350,000-25,972,000-25,064,000-13,160,000-23,208,000
EBT Margin-100.0%-0.21-0.82-0.89-0.90-0.87-0.73-0.65-0.36-0.11-0.24-0.22-0.40-0.38-0.30-0.31-0.17-0.28
Net Income361.1%66,354,00014,390,000-149,186,000-152,692,000-147,846,000-135,130,000-100,393,000-81,639,000-42,780,000-11,876,000-24,463,000-21,254,000-36,614,000-33,275,000-24,571,000-24,110,666-13,150,000-23,392,000
Net Income Margin-100.0%-0.07-0.82-0.90-0.91-0.87-0.73-0.65-0.35-0.09-0.23-0.20-0.37-0.36-0.29-0.30-0.16-0.28
Free Cashflow100.0%--120,964,000-127,697,000-122,104,000-102,164,000-107,820,000-77,836,000-14,409,000-13,345,0009,406,00014,219,000-39,935,000-33,795,000-28,828,000-27,895,000-21,964,000-20,512,000-22,752,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets0.3%842839689662688720756763717744746680350350155
  Current Assets-1.9%592604534524557586625622650675683621307313119
    Cash Equivalents22.6%28623390.0010313112112316412113420321111114526.00
  Net PPE23.4%20.0016.0014.0014.0012.0011.0010.009.007.005.005.005.006.006.006.00
  Goodwill0%5.005.005.005.005.005.00---------
Liabilities-7.3%23024924119919518919918311211212249.0053.0054.0057.00
  Current Liabilities-13.5%10712310989.0086.0086.0091.0073.0070.0068.0073.0039.0043.0042.0045.00
Shareholder's Equity3.6%611590448463493531557580606632624631296296-
  Retained Earnings1.7%-245-250-379-351-312-264-229-199-164-129-129-118-122-118-105
  Additional Paid-In Capital2.0%85784082981880879778777876976175374841741412.00
Shares Outstanding0.2%72.0071.0062.0071.0071.0071.0062.0071.0071.0070.0061.0066.0063.0041.006.00
Minority Interest---0.000.000.000.000.000.000.000.000.000.000.000.000.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations5.6%-104-111-119-114-94.75-99.46-70.67-7.31-8.7112.0017.00-38.13-32.02-27.21-26.06-19.73-17.73-18.49
  Share Based Compensation3.3%43.0041.0040.0037.0035.0031.0026.0022.0017.0013.0011.008.006.003.002.002.002.002.00
Cashflow From Investing14.6%25922690.0056.0010181.00-16.81-47.96-316-355-381-322-111-125-53.85-80.31-109-64.31
Cashflow From Financing199.5%6.002.002.003.004.005.008.008.0033533254153821023629.0041.0060.0021.00

SDGR Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 35,189$ 38,469$ 99,971$ 87,132
Cost of revenues:    
Total cost of revenues21,37921,33540,46842,015
Gross profit13,81017,13459,50345,117
Operating expenses:    
Research and development42,70531,12383,44658,945
Sales and marketing9,0227,42818,16714,099
General and administrative23,21622,05649,52444,189
Total operating expenses74,94360,607151,137117,233
Loss from operations(61,133)(43,473)(91,634)(72,116)
Other income (expense):    
Gain on equity investments011,828147,32211,828
Change in fair value40,654(15,700)76,391(21,864)
Other income (expense)4,326(308)7,26331
Total other income (expense)44,980(4,180)230,976(10,005)
(Loss) income before income taxes(16,153)(47,653)139,342(82,121)
Income tax (benefit) expense(20,431)335,9285
Net income (loss)$ 4,278$ (47,686)$ 133,414$ (82,126)
Earnings Per Share [Abstract]    
Net income (loss) per share of common and limited common stockholders, basic (in USD per share)$ 0.06$ (0.67)$ 1.86$ (1.15)
Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, basic (in shares)71,642,72271,161,89271,555,39571,106,470
Net income (loss) per share of common and limited common stockholders, diluted (in USD per share)$ 0.06$ (0.67)$ 1.79$ (1.15)
Weighted average shares used to compute net income (loss) per share of common and limited common stockholders, diluted: (in shares)75,064,32371,161,89274,499,67271,106,470
Software products and services    
Revenues:    
Total revenues$ 29,352$ 30,011$ 61,565$ 63,092
Cost of revenues:    
Total cost of revenues6,6957,10113,81014,612
Drug discovery    
Revenues:    
Total revenues5,8378,45838,40624,040
Cost of revenues:    
Total cost of revenues$ 14,684$ 14,234$ 26,658$ 27,403

SDGR Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 285,963$ 90,474
Restricted cash5,0535,243
Marketable securities262,710360,613
Accounts receivable, net of allowance for doubtful accounts of $250 and $1259,65255,953
Unbilled and other receivables, net for allowance for unbilled receivables of $100 and $10014,58513,137
Prepaid expenses13,9998,569
Total current assets591,962533,989
Property and equipment, net20,35314,244
Equity investments106,40425,683
Goodwill4,7914,791
Intangible assets, net0587
Right of use assets112,984105,982
Other assets5,0723,311
Total assets841,566688,587
Current liabilities:  
Accounts payable12,4289,470
Income taxes payable5,134355
Accrued payroll, taxes, and benefits21,32824,882
Deferred revenue46,67457,931
Lease liabilities13,92111,006
Other accrued liabilities7,3175,166
Total current liabilities106,802108,810
Deferred revenue, long-term15,62025,598
Lease liabilities, long-term107,319105,485
Other liabilities, long-term600800
Total liabilities230,341240,693
Commitments and contingencies (Note 5)
Stockholders' equity:  
Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital856,913828,700
Accumulated deficit(245,724)(379,138)
Accumulated other comprehensive loss(683)(2,382)
Total stockholders' equity611,225447,894
Total liabilities and stockholders' equity841,566688,587
Common Stock  
Stockholders' equity:  
Common and Limited Stock627622
Limited common stock  
Stockholders' equity:  
Common and Limited Stock$ 92$ 92
Ramy Farid
660
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.